** Shares of biotech firm Humacyte HUMA.O down 23.5% to $2.20 post-market after stock offering news
** Durham, North Carolina-based firm announces proposed stock offering without disclosing deal size
** Co intends to use net offering proceeds to fund commercialization of its implant Symvess for patients with extreme blood vessel injury
** TD Cowen, Barclays and BTIG jt bookrunners
** With ~122.65 mln shares outstanding, co has ~$353 mln market cap, per LSEG data
** HUMA shares finished Tuesday's session down 13.4% at $2.88. YTD, stock down 43%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。